Fig. 4
Disease progression over time – (A) Baseline, (B) Faricimab 6 mg at 8 weeks, and (C) Follow-up at 18 months with treat-and-extend Faricimab 6 mg regimen. Reduction in intraretinal fluid and PED volume can be observed
Fig. 4 | Scientific Reports
